+Compare
UTRS
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
14.74M

UTRS Minerva Surgical Forecast, Technical & Fundamental Analysis

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for UTRS with price predictions
07:00 PM EST Nov 27, 2023

Momentum Indicator for UTRS turns negative, indicating new downward trend

UTRS saw its Momentum Indicator move below the 0 level on November 03, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator turned negative. In of the 34 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for UTRS turned negative on November 07, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UTRS advanced for three days, in of 68 cases, the price rose further within the following month. The odds of a continued upward trend are .

UTRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.765) is normal, around the industry mean (25.167). P/E Ratio (0.000) is within average values for comparable stocks, (79.649). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.240). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.210) is also within normal values, averaging (45.457).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. UTRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Align Technology (NASDAQ:ALGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 6.4B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 2%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was 703%. ICCM experienced the highest price growth at 85%, while SLDX experienced the biggest fall at -83%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 47%. For the same stocks of the Industry, the average monthly volume growth was 49% and the average quarterly volume growth was 79%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 69
Price Growth Rating: 55
SMR Rating: 84
Profit Risk Rating: 88
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

UTRS is expected to report earnings to rise 80.00% to -9 cents per share on November 30

Minerva Surgical UTRS Stock Earnings Reports
Q3'23
Est.
$-0.09
Q2'23
Beat
by $0.04
Q1'23
Beat
by $0.11
Q4'22
Beat
by $0.08
Q3'22
Missed
by $0.12
The last earnings report on August 02 showed earnings per share of -5 cents, beating the estimate of -9 cents. With 15.73K shares outstanding, the current market capitalization sits at 14.74M.
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
4255 Burton Drive
Phone
+1 855 646-7874
Employees
174
Web
https://www.minervasurgical.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DNA1.440.05
+3.60%
Ginkgo Bioworks Holdings
OXSQ2.900.03
+1.05%
Oxford Square Capital Corp
IMPL0.60N/A
-0.23%
Impel Pharmaceuticals
NOK3.52-0.02
-0.56%
Nokia Corp
ASLE14.00-0.25
-1.75%
AerSale Corp

UTRS and

Correlation & Price change

A.I.dvisor tells us that UTRS and STSS have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that UTRS and STSS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UTRS
1D Price
Change %
UTRS100%
-1.20%
STSS - UTRS
27%
Poorly correlated
-1.29%
FEMY - UTRS
24%
Poorly correlated
-1.94%
MYSZ - UTRS
22%
Poorly correlated
+0.18%
GDEV - UTRS
22%
Poorly correlated
+4.74%
CETXP - UTRS
21%
Poorly correlated
N/A
More

Groups containing UTRS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UTRS
1D Price
Change %
UTRS100%
-1.20%
Medical Specialties
(undefined stocks)
-2%
Poorly correlated
+0.15%
Medical Specialties
(undefined stocks)
-2%
Poorly correlated
+0.15%